Notes
CARES = Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities
Reference
Gillian A. Febuxostat: increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study. Internet Document : [3 pages], 27 Jun 2019. Available from: URL: https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---febuxostat.pdf?sfvrsn=0
Rights and permissions
About this article
Cite this article
Febuxostat: higher risk of CV-related death, all-cause mortality. Reactions Weekly 1761, 2 (2019). https://doi.org/10.1007/s40278-019-64374-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-64374-4